immunoscore
Showing 1 - 25 of 40
Role of Immunoscore® in Stage II-III Colorectal Cancer
Recruiting
- Colon Adenocarcinoma
- Immunoscore Colon Test
-
Brasília, Distrito Federal, Brazil
- +1 more
Jun 14, 2022
Non Metastatic Colorectal Cancer Trial in Marseille (IMMUNOSCORE®)
Recruiting
- Non Metastatic Colorectal Cancer
- IMMUNOSCORE®
-
Marseille, France
- +1 more
Apr 12, 2022
Rectal Cancer Trial in Guangzhou (Sintilimab)
Recruiting
- Rectal Cancer
-
Guangzhou, Guangdong, ChinaDepartment of colorectal surgery, the Sixth Affiliated Hospital,
Jul 11, 2022
Colon Cancer Stage III Trial in Vienna (drug, device, other)
Not yet recruiting
- Colon Cancer Stage III
- Capecitabine
- +5 more
-
Vienna, AustriaMedical University of Vienna
Mar 26, 2022
NSCLC Trial in Denmark, Norway (Will look for immune infiltration)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Will look for immune infiltration
-
København, København Ø, Denmark
- +4 more
Jan 6, 2022
The Immunoscore as a Prognostic Marker for a Colorectal Cancer
Active, not recruiting
- Colorectal Cancer
- Surgical Resection of the Colorectal Tumor
-
Besançon, France
- +5 more
Oct 11, 2021
Stage II Colon Cancer, Adjuvant Chemo Trial (FOLFOX/XELOX/Capecitabine)
Not yet recruiting
- Stage II Colon Cancer
- Adjuvant Chemotherapy
- (no location specified)
Apr 6, 2020
Oral Leukoplakia, Oral Leukoplakia of Tongue, Oral Leukoplakia of Gingiva Trial in Erlangen
Recruiting
- Oral Leukoplakia
- +3 more
-
Erlangen, GermanyUniversitätsklinikum Erlangen, FAU Erlangen-Nürnberg
Dec 2, 2019
Personalizing Colorectal Cancer Medicine (ImmuCol2)
Active, not recruiting
- Colon Cancer
-
Besançon, France
- +8 more
Oct 11, 2021
Colonic Tumors Trial in France (Immunoscore Colon Test)
Withdrawn
- Colonic Neoplasms
- Immunoscore Colon Test
-
Blois, France
- +20 more
Aug 27, 2019
Colon Cancer Trial in San Antonio (PalloV-CC)
Recruiting
- Colon Cancer
- PalloV-CC
-
San Antonio, TexasClinical Associates of Research Therapeutics of America
Sep 14, 2022
NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Phase I - Mirdametinib - Level 1
- +4 more
- (no location specified)
Jul 7, 2023
Rectal Adenocarcinoma Trial in Portland (LY2157299, Capecitabine, Fluorouracil)
Active, not recruiting
- Rectal Adenocarcinoma
- LY2157299
- +3 more
-
Portland, OregonProvidence Cancer Center
Mar 22, 2022
Colon Cancer Trial in Slagelse (Metformin Hydrochloride, Placebo oral capsule)
Completed
- Colon Cancer
- Metformin Hydrochloride
- Placebo oral capsule
-
Slagelse, DenmarkDepartment of Surgery, Slagelse Hospital
Mar 2, 2022
Glioblastoma Multiforme of Brain Trial in Gatineau (avelumab)
Completed
- Glioblastoma Multiforme of Brain
- avelumab
-
Gatineau, Quebec, CanadaClinique Neuro-Outaouais
Jul 19, 2022
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph
Recruiting
- Triple Negative Breast Cancer
- +2 more
- Radiation Therapy Boost
- +6 more
-
Washington, District of Columbia
- +8 more
Dec 5, 2022
Colorectal Tumors, Tumor Metastasis, Colonic Tumors Trial in Seoul (Atezolizumab, Bevacizumab, Oxaliplatin)
Active, not recruiting
- Colorectal Neoplasms
- +3 more
- Atezolizumab
- +4 more
-
Seoul, Songpa-gu, Korea, Republic ofAsan Medical Center
Jul 6, 2022
Endometrial Serous Adenocarcinoma Trial in United States (Biospecimen Collection, Resection, Triapine)
Recruiting
- Endometrial Serous Adenocarcinoma
- Biospecimen Collection
- +2 more
-
Coral Gables, Florida
- +5 more
Aug 23, 2022
Triple Negative Breast Cancer Trial in Washington, Chicago, Hackensack (Nivolumab, Capecitabine)
Active, not recruiting
- Triple Negative Breast Cancer
-
Washington, District of Columbia
- +3 more
Mar 14, 2022
COLON-IM : Microbiota and Immune Infiltrate in Normal,
Recruiting
- Colorectal Cancer
-
Lyon, France
- +1 more
Jul 22, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Buffalo
Active, not recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Aldesleukin
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Mar 3, 2022
Melanoma Trial in Italy (Cobimetinib 20 MG Oral Tablet, Vemurafenib 240 Mg Oral Capsule, Atezolizumab 1200 MG in 20 ML
Recruiting
- Melanoma
- Cobimetinib 20 MG Oral Tablet
- +2 more
-
Bagno A Ripoli, Firenze, Italy
- +5 more
Apr 12, 2022
Immune Biomarker Study for Head and Neck Cancer
Recruiting
- Head and Neck Cancer
- +4 more
- Sampling
-
Erlangen, Bavaria, Germany
- +2 more
Jan 23, 2023
Immunoscore in Rectal Cancer
Completed
- Cancer of the Rectum
- +4 more
- Diagnostic Biopsy and Surgical Procedure
- +3 more
-
Portland, Oregon
- +1 more
Aug 27, 2018
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma Trial in Houston (Durvalumab,
Recruiting
- Metastatic Angiosarcoma
- +7 more
- Durvalumab
- Oleclumab
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2021